후성유전학 진단 시장 규모, 점유율, 성장 분석 : 기술별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Epigenetics Diagnostics Market size was valued at USD 15.5 Billion in 2024 and is poised to grow from USD 18.06 Billion in 2025 to USD 61.27 Billion by 2033, growing at a CAGR of 16.5% during the forecast period (2026-2033).

The global epigenetics diagnostics market is experiencing significant growth, driven by advancements in high-throughput sequencing and analysis. These innovations enable the identification of critical epigenetic markers, including DNA methylation and histone modifications, which are vital for detecting disease. Epigenetic changes serve as early indicators of various conditions, making them crucial for diagnosis and treatment, as targeted therapies can potentially reverse these modifications. As sensitivity in sequencing and bioinformatics improves, reimbursement for epigenetic testing by payers is expected to increase, facilitating commercialization. Furthermore, the demand for scalable laboratory platforms will rise, particularly with emerging multi-cancer blood tests, prompting collaboration between diagnostic firms and sequencing technology providers. This synergy supports the delivery of comprehensive cancer solutions and preconception risk assessments worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Epigenetics Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Epigenetics Diagnostics Market Segments Analysis

Global epigenetics diagnostics market is segmented by technology, application, end-user and region. Based on technology, the market is segmented into DNA Methylation, Histone Modification, Non-Coding RNA Analysis and Others. Based on application, the market is segmented into Oncology, Cardiovascular Diseases, Neurology and Others. Based on end-user, the market is segmented into Reference Laboratories, Hospital Diagnostic Labs and Academic Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Epigenetics Diagnostics Market

One of the key market drivers for the global epigenetics diagnostics market is the increasing prevalence of chronic diseases and cancer, which have heightened the demand for advanced diagnostic tools. As the understanding of the epigenetic mechanisms underlying disease progression improves, there is a growing need for innovative diagnostic solutions that can provide insights into individual patient profiles and personalized treatment strategies. Additionally, advancements in technology, such as next-generation sequencing and bioinformatics, are facilitating the development of more accurate and cost-effective epigenetic tests, further propelling market growth and expanding applications in clinical and research settings.

Restraints in the Global Epigenetics Diagnostics Market

One of the key market restraints for the global epigenetics diagnostics market is the high cost associated with advanced diagnostic tools and technologies. The sophisticated nature of epigenetic analysis requires significant investment in research, development, and manufacturing, leading to elevated prices for both providers and patients. Additionally, the complexity of interpreting epigenetic data poses challenges in clinical settings, potentially limiting adoption among healthcare practitioners. Furthermore, regulatory hurdles and the need for extensive validation studies can slow down the introduction of innovative products, creating barriers for market entry and reducing overall accessibility for patients and healthcare systems.

Market Trends of the Global Epigenetics Diagnostics Market

The Global Epigenetics Diagnostics market is experiencing significant growth driven by the integration of precision oncology practices that leverage epigenetics-based diagnostic tools for enhanced patient stratification. Clinicians and researchers increasingly recognize the value of epigenetic markers in cancer diagnosis, prognosis, and drug response prediction, fostering collaboration between diagnostic manufacturers and the oncology sector. This trend is paving the way for the development of companion diagnostics and the standardization of assays in clinical laboratories, which, in turn, supports personalized therapy regimens. The emphasis on practical applications and seamless integration into clinical decision-making processes is shaping the future of epigenetic diagnostics in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Epigenetics Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• DNA Methylation
• Histone Modification
• Non-Coding RNA Analysis
• Others

Global Epigenetics Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
  • Liquid Biopsy Cancer Screening
  • Solid Tumor Profiling
• Cardiovascular Diseases
  • Stroke Risk Assessment
  • Myocardial Infarction Markers
• Neurology
• Others

Global Epigenetics Diagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Reference Laboratories
• Hospital Diagnostic Labs
• Academic Research Institutes

Global Epigenetics Diagnostics Market Size & CAGR (2026-2033)

• North America (Technology, Application, End-User)
  • US
  • Canada
• Europe (Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revvity
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonic Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations